Tigecycline

Tigecycline is the first commercially available antibiotic of the glycylcycline class, which are a new family based on tetracyclines, but with molecular modifications to evade some, but not all, tetracycline resistance mechanisms. Tetracycline resistance...

Its labeled indications are:

Complicated Appendicitis Complicated Bacterial Peritonitis Complicated Skin and Skin Structure Infection Complicated Skin and Skin Structure E. coli Infection Complicated Skin and Skin Structure Enterococcus faecalis Infection,

Complicated Skin and Skin Structure Staphylococcus aureus Infection Complicated Skin and Skin Structure Streptococcus agalactiae Infection Complicated Skin and Skin Structure Streptococcus pyogenes Infection Haemophilus influenzae Pneumonia,

Infectious Disease of Abdomen Intra-Abdominal Abscess* Legionella pneumophila Pneumonia Streptococcal Pneumonia

Mechanism of action

The drug evades the Tet(A-E) efflux pumps which account for most acquired resistance to tetracycline and minocycline in Enterobacteriaceae and Acinetobacter spp.; also the Tet(K) pumps, which occur widely in staphylococci conferring resistance to tetracycline though not minocycline or doxycycline. It binds to bacterial ribosomes that have been modified by the Tet(M) protein, a mechanism that compromises all available tetracyclines, and which is frequent in Gram-positive cocci and Neisseriae spp.

Administration

It is given intravenously, but should not be administered simultaneously, through common tubing, with amphotericin B, chlorpromazine, methylprednisolone, or voriconazole.